• Molecular NameBezafibrate
  • SynonymBezafibrat; Bezafibrato [inn-spanish]; Bezafibratum [inn-latin]
  • Weight327.38
  • Drugbank_IDDB01393
  • ACS_NO41859-67-0
  • Show 2D model
  • LogP (experiment)4.2
  • LogP (predicted, AB/LogP v2.0)3.08
  • pkaN/A
  • LogD (pH=7, predicted)0.1
  • Solubility (experiment)0.0162 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)0.12
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.33
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds7
  • TPSA75.63
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA fibrate drug used for the treatment of hyperlipidaemia. It helps to lower LDL cholesterol and triglyceride in the blood, and increase HDL.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability99.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life2
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe main toxicity is hepatic (abnormal liver enzymes), and myopathy and rarely rhabdomyolysis have been reported.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A